Eli Lilly and Company (SWX:LLY)

Market Cap	574.73B
Revenue (ttm)	42.36B
Net Income (ttm)	10.97B
Shares Out	n/a
EPS (ttm)	12.16
PE Ratio	52.37
Forward PE	29.03
Dividend	4.98 (0.79%)
Ex-Dividend Date	Aug 15, 2025

Volume	n/a
Average Volume	3
Open	n/a
Previous Close	615.00
Day's Range	n/a
52-Week Range	538.92 - 805.00
Beta	0.33
RSI	48.58
Earnings Date	Oct 30, 2025

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Ja...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1876
• Employees: 47,000
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: LLY

Financial Performance

In 2024, Eli Lilly and Company's revenue was $45.04 billion, an increase of 32.00% compared to the previous year's $34.12 billion. Earnings were $10.59 billion, an increase of 102.08%.

Financial numbers in USD